Summary of CLL samples
Patient code . | TL . | TA . | RAI . | Viability index . |
|---|---|---|---|---|
| 001TA | 7.4 | − | NA | 25 |
| 002GB | 7.1 | + | IV | 97 |
| 003ZW | 5.4 | − | III | 1 |
| 004LW | 5.9 | + | II | 9 |
| 005GP | 6.9 | − | 0 | 2 |
| 006GK | 7.2 | + | II | 1 |
| 007TK | 6.6 | + | IV | 2 |
| 008RH | 6.9 | − | II | 34 |
| 009SH | 6.9 | + | II | 1 |
| 010IK | 6.9 | − | II | 4 |
| 011HH | 6.5 | − | II | 31 |
| 012CG | 5.7 | + | IV | 80 |
| 013SE | 8.5 | − | IV | 89 |
| 014TP | 7.4 | − | II | 1 |
| 015BJ | 7.8 | − | I | 1 |
| 016VG | 7.7 | − | I | 98 |
| 017FL | 7.3 | − | II | 2 |
| 018DM | 5.4 | + | IV | 8 |
| 019WA | 5.2 | − | IV | 5 |
| 020MH | 6.2 | + | 0 | 1 |
Patient code . | TL . | TA . | RAI . | Viability index . |
|---|---|---|---|---|
| 001TA | 7.4 | − | NA | 25 |
| 002GB | 7.1 | + | IV | 97 |
| 003ZW | 5.4 | − | III | 1 |
| 004LW | 5.9 | + | II | 9 |
| 005GP | 6.9 | − | 0 | 2 |
| 006GK | 7.2 | + | II | 1 |
| 007TK | 6.6 | + | IV | 2 |
| 008RH | 6.9 | − | II | 34 |
| 009SH | 6.9 | + | II | 1 |
| 010IK | 6.9 | − | II | 4 |
| 011HH | 6.5 | − | II | 31 |
| 012CG | 5.7 | + | IV | 80 |
| 013SE | 8.5 | − | IV | 89 |
| 014TP | 7.4 | − | II | 1 |
| 015BJ | 7.8 | − | I | 1 |
| 016VG | 7.7 | − | I | 98 |
| 017FL | 7.3 | − | II | 2 |
| 018DM | 5.4 | + | IV | 8 |
| 019WA | 5.2 | − | IV | 5 |
| 020MH | 6.2 | + | 0 | 1 |
Indicated is the classification for the patients according to RAI staging system. Telomerase activity (TA) was determined using the TRAP (PCR ELISAPLUS) assay, the mean telomere length (TL) was measured using flow-FISH. The response to 80 μM BIBR1532 is expressed as viability index representing the viable cells as percentage of controls after 2 weeks of cell culture. All experimental conditions were performed in duplicates.
— indicates negative; NA, not available; and +, positive.